SI-BONE, Inc. (FRA:2K3)
Germany · Delayed Price · Currency is EUR | Market Cap | 750.43M +26.6% |
| Revenue (ttm) | 186.97M +15.3% |
| Net Income | -12.81M |
| EPS | -0.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 16.30 |
| Previous Close | 16.50 |
| Day's Range | 16.30 - 16.50 |
| 52-Week Range | 9.65 - 17.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About SI-BONE
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the impla... [Read more]
Financial Performance
In 2025, SI-BONE's revenue was $200.93 million, an increase of 20.19% compared to the previous year's $167.18 million. Losses were -$18.90 million, -38.85% less than in 2024.
Financial numbers in USD Financial StatementsNews
SI-Bone price target raised to $25 from $24 at UBS
UBS analyst Patrick Wood raised the firm’s price target on SI-Bone (SIBN) to $25 from $24 and keeps a Buy rating on the shares. SI-Bone posted a “solid” print and…
SI-Bone price target raised to $20 from $18 at TD Cowen
TD Cowen analyst Mathew Blackman raised the firm’s price target on SI-Bone (SIBN) to $20 from $18 and keeps a Buy rating on the shares. The firm said with strong…
SI-Bone price target raised to $23 from $21 at Truist
Truist raised the firm’s price target on SI-Bone (SIBN) to $23 from $21 and keeps a Buy rating on the shares. The company delivered accelerating revenue growth, stronger procedures, and…
SI-Bone sees FY26 revenue $231M-$233M, consensus $231.79M
The company is maintaining FY26 gross margin guidance at ~79%, and updating operating expenses guidance to now be ~12% compared to the prior guidance of ~12.5%.
SI-Bone reports Q2 EPS (9c), consensus (15c)
Reports Q2 revenue $56.0M, consensus $55.4M. “Our accelerating growth and expanding profitability reinforces our conviction in the demand for our superior platform technologies and the significant run...
SI-BONE Earnings Call Transcript: Q2 2026
Q2 2026 delivered 15% revenue growth, strong operating leverage, and a narrowed net loss, driven by broad-based demand and new product momentum. Guidance was raised, with multiple catalysts expected in H2 2026, including a new breakthrough device launch and higher reimbursement.
SI-BONE Earnings release: Q2 2026
SI-BONE released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
SI-BONE Slides: Q2 2026
SI-BONE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
SI-BONE Quarterly report: Q2 2026
SI-BONE has published its Q2 2026 quarterly earnings report on August 3, 2026.
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base
SI-Bone initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of SI-Bone (SIBN) with a Buy rating and $24 price target The firm anticipates an innovation supercycle, the analyst tells investors in a research…
SI-Bone initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of SI-Bone (SIBN) with a Buy rating and $24 price target
SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-Bone price target raised to $21 from $18 at Truist
Truist raised the firm’s price target on SI-Bone (SIBN) to $21 from $18 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its ...
SI-BONE Transcript: Truist Securities MedTech Conference 2026
The company has evolved into a multi-product platform targeting a $3.5B TAM, with strong growth in SI joint, trauma, and pelvic fixation markets. Physician base and sales force expansion, new product launches, and partnerships like Smith+Nephew are expected to drive accelerated growth and improved reimbursement through 2028.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bon...
SI-BONE Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, all of which were approved. No questions were raised, and a quorum was established with nearly 88% of shares represented. Final voting results will be filed on Form 8-K.
SI-Bone management to meet with Needham
Meeting to be held in Boston on June 1 and in New York on June 2 hosted by Needham.
SI-Bone price target lowered to $18 from $22 at TD Cowen
TD Cowen analyst Mathew Blackman lowered the firm’s price target on SI-Bone (SIBN) to $18 from $22 and keeps a Buy rating on the shares. The firm said sales and…
SI-BONE Transcript: Bank of America Global Healthcare Conference 2026
Momentum is driven by innovation, expanding physician adoption, and strategic partnerships, with new products and reimbursement changes expected to accelerate growth and profitability through 2026 and beyond. Gross margins remain strong near 80%, and operating leverage is set to improve.
SI-Bone price target lowered to $18 from $20 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on SI-Bone (SIBN) to $18 from $20 and keeps a Buy rating on the shares. The firm notes that its reduced…
SI-Bone reports Q1 EPS (10c), consensus (19c)
Reports Q1 revenue $52.6M, consensus $51.16M. “The first quarter demonstrated the strength and durability of our platform, with record physician engagement and double-digit growth across all key metri...
SI-Bone raises FY26 revenue view $230M-$233M from $228.5M-$232.5M
Consensus $230.44M. Sees gross margin 79%; positive adjusted EBITDA.
SI-BONE Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth, strong operating leverage, and raised full-year guidance. New product launches, a key partnership, and favorable CMS reimbursement changes are expected to accelerate growth, with a breakthrough device launch and expanded sales force supporting future momentum.